AZD 8601

Drug Profile

AZD 8601

Alternative Names: AZD-8601

Latest Information Update: 06 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca; Moderna Therapeutics
  • Developer AstraZeneca; Moderna Therapeutics; The Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre
  • Class Cardiovascular therapies; RNA
  • Mechanism of Action Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • Preclinical Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 01 Dec 2016 Phase-I clinical trials in Type-2 diabetes mellitus in Germany (Intradermal) (NCT02935712)
  • 26 Jul 2016 Preclinical trials in Metabolic disorders in USA (Parenteral)
  • 26 Jul 2016 AstraZeneca and Moderna Therapeutics file a clinical trial application (CTA) with the Paul Ehrlich Institute and the German Federal Ministry of Health in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top